Hormonal
Liraglutide treatment is associated with decreased liver fibrosis in patients with type 2 diabetes, as evidenced by lower NAFLD fibrosis score (NFS), FIB-4, and liver stiffness measurement (LSM) after 12 months.
If you have Type 2 Diabetes, ask your doctor about Liraglutide. This medication has been shown to be associated with reduced markers of liver scarring (fibrosis) over a year of use. This is particularly relevant if you are at risk for Non-Alcoholic Fatty Liver Disease (NAFLD), which is common in T2DM. The benefit appears to be linked to its hormonal effects and weight loss.
Liraglutide treatment is associated with decreased liver fibrosis in type 2 diabetic subjects.
Why this rating
Prospective cohort study with propensity score matching, but observational design limits causal inference compared to RCTs.
Source
Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes
Yijiong Tan et al. · Frontiers in Endocrinology · 2022
DOI 10.3389/fendo.2022.935180
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →